The future of diabetes treatment.
Petersen
J S
JS
Novo Nordisk, Novo Nordisk Park 1, Maaloev, Denmark. jspe@novonordisk.com
D000818:Animals; D003920:Diabetes Mellitus / Q000188:drug therapy*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D052216:Glucagon-Like Peptide 1 / Q000494:pharmacology; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D050417:Insulin-Secreting Cells / Q000187:drug effects
D007004:Hypoglycemic Agents; D052216:Glucagon-Like Peptide 1